With 6 years of dedicated work at Paras Biopharmaceuticals and the use of Paras Biopharmaceuticals’ unique technology platform (which comprises Bioproduction technologies for economical production of biologics), the company has announced that an excellent scale-up production process is achieved with “Continuous Biomanufacturing”. These developments are described at https://www.parasbiopharma.com/biosimilars/biosimilars.php for Urology & Onco-immunology Biosimilars which require the highest level of control during manufacturing to achieve high quality. Paras Biopharmaceuticals’ efforts on “Continuous Biomanufacturing” results in high yield and low manufacturing costs of high-value onco-immunology and urology biosimilar development.
“Paras Biopharmaceuticals experienced very difficult challenges in scale-up production of these biologics, however, due to Paras Biopharmaceuticals’ unique technology platform being very versatile, the company overcame critical manufacturing challenges, and quickly resolved these issues,” said Dr Ashesh Kumar, CEO, Paras Biopharmaceuticals Finland Oy
“Paras Biopharma has streamlined its high-value biosimilar co-development partnership under “Paras Biologics”. The company brings Onco-Immunology & Urology Biosimilars to our partners, to take a potential leadership position with these developments,” added Dr Mark Jackson, Admin Lead, Paras Biopharmaceuticals Finland Oy.
Read more information about Paras Biopharmaceuticals.
Contact person
Dr. Mark Jackson
Media Relations & Information, Paras Biopharmaceuticals
mark.jackson@parasbiopharma.com
Source: Paras Biopharmaceuticals